These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3110845)

  • 1. Does DGAVP influence memory, attention and mood in young healthy men?
    Snel J; Taylor J; Wegman M
    Psychopharmacology (Berl); 1987; 92(2):224-8. PubMed ID: 3110845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects.
    Bruins J; Kumar A; Schneider-Helmert D
    Neuropsychobiology; 1990; 23(2):82-8. PubMed ID: 2077437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of acute and chronic treatment with desglycinamide-[Arg8]vasopressin in young male and female volunteers.
    Bruins J; Hijman R; Van Ree JM
    Peptides; 1995; 16(2):179-86. PubMed ID: 7784246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of DGAVP on verbal memory.
    Pietrowsky R; Fehm-Wolfsdorf G; Born J; Fehm HL
    Peptides; 1988; 9(6):1361-6. PubMed ID: 3247253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of desglycinamide-arginine-vasopressin (DGAVP) on memory in patients with korsakoff's syndrome.
    Laczi F; Van Ree JM; Balogh L; Szász A; Járdánházy T; Wágner A; Gáspár L; Valkusz Z; Dobranovics I; Szilárd J
    Acta Endocrinol (Copenh); 1983 Oct; 104(2):177-82. PubMed ID: 6637330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in patients with dementia.
    Peabody CA; Thiemann S; Pigache R; Miller TP; Berger PA; Yesavage J; Tinklenberg JR
    Neurobiol Aging; 1985; 6(2):95-100. PubMed ID: 3895014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin fragment, AVP-(4-8), improves long-term and short-term memory in the hole board search task.
    Vawter MP; De Wied D; Van Ree JM
    Neuropeptides; 1997 Oct; 31(5):489-94. PubMed ID: 9413027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of desglycinamide-(Arg8)-vasopressin (DGAVP) on the acquisition of free-choice alcohol drinking in rhesus monkeys.
    Kornet M; Goosen C; Ribbens LG; Van Ree JM
    Alcohol Clin Exp Res; 1991 Feb; 15(1):72-9. PubMed ID: 2024735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects.
    Westenberg HG; Hijman R; Wiegant VM; Laczi F; Van Ree JM
    Peptides; 1994; 15(6):1101-4. PubMed ID: 7991455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Functional activity of vasopressin analog desglycinamide-arginine-vasopressin].
    Golubeva MG
    Izv Akad Nauk Ser Biol; 2006; (3):297-305. PubMed ID: 16771143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of a vasopressin-analogue (DGAVP) on event-related potentials in a stimulus-mismatch paradigm.
    Pietrowsky R; Born J; Fehm-Wolfsdorf G; Fehm HL
    Biol Psychol; 1989 Jun; 28(3):239-50. PubMed ID: 2686760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of DGAVP on acquisition and extinction of active avoidance behavior.
    Skopkova J; Croiset G; De Wied D
    Peptides; 1991; 12(3):471-5. PubMed ID: 1923926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma.
    Bohnen NI; Twijnstra A; Jolles J
    Neurology; 1993 Jan; 43(1):103-6. PubMed ID: 8423870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention of ethanol tolerance by desglycinamide-arginine-vasopressin occurs in the absence of changes in hippocampal serotonin synthesis.
    Speisky MB; Kalant H
    Alcohol Alcohol Suppl; 1987; 1():455-9. PubMed ID: 3426715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced monoaminergic neurotransmission by desglycinamide-arginine-vasopressin in human subjects.
    Jolkkonen J; Lehtinen M; Soininen H; Sennef C; Riekkinen P
    Neurosci Lett; 1987 May; 76(3):312-5. PubMed ID: 2438607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects.
    Riekkinen P; Legros JJ; Sennef C; Jolkkonen J; Smitz S; Soininen H
    Peptides; 1987; 8(2):261-5. PubMed ID: 3588346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical trial with desglycinamide arginine vasopressin for the treatment of memory disorders in man.
    Jennekens-Schinkel A; Wintzen AR; Lanser JB
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(3):273-84. PubMed ID: 3898228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting effects of vasopressin, desglycinamide-vasopressin and amphetamine on a delayed matching to position task in rats.
    Sahgal A
    Psychopharmacology (Berl); 1987; 93(2):243-9. PubMed ID: 3122257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin and amphetamine, but not desglycinamide vasopressin, impair positively reinforced visual attention performance in rats.
    Sahgal A
    Behav Brain Res; 1988 Jul; 29(1-2):35-42. PubMed ID: 3401320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of AVP and DGAVP on the exploratory activity of rats.
    Skopková J; Lát J; Dvorská I; Hrbas P; Radil T
    Peptides; 1987; 8(5):785-90. PubMed ID: 3432126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.